Want to see IL:BLRX full AI Analyst Report?
BLRX Stock Chart & Stats
1.50
0.10(6.67%)
At close: 4:00 PM EDT
1.50
0.10(6.67%)
Day’s Range― - ―
52-Week Range1.10 - 2.40
Previous CloseN/A
Volume0.00
Average Volume (3M)3.94M
Market Cap
₪38.83M
Enterprise Value33.16
Total Cash (Recent Filing)₪12.99M
Total Debt (Recent Filing)₪7.94M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Nov 18, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,986,929,700
10 Day Avg. Volume4,534,387
30 Day Avg. Volume3,943,821
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.68
Price to Sales (P/S)9.69
P/FCF Ratio-1.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)₪1.95M
Bulls Say, Bears Say
Bulls Say
GLIX1 Clinical ExecutionGLIX1 recruitment is ahead of plan, multiple academic centers are enrolling, and safety and tolerability have remained encouraging. This execution supports development momentum and expands the evidence base for a potentially differentiated oncology asset, although value still depends on later clinical readouts.
Differentiated Oncology OpportunityGLIX1 combines an oral, first-in-class mechanism with blood-brain barrier penetration and activity in difficult glioma models. These characteristics could support differentiation in an area with limited treatment improvement, creating meaningful strategic potential if clinical results validate the preclinical profile.
Partner-generated Royalty PlatformAPHEXDA provides commercial exposure and royalty income without requiring BioLineRx to build the entire sales infrastructure itself. Although current royalties are modest, partner-led sales create a recurring economic stream and preserve upside from broader adoption of the approved product.
Bears Say
Severe Revenue And Profitability WeaknessThe sharp revenue collapse and deeply negative net margin show that current commercial income is far below the cost base. This weak earnings foundation limits internally funded investment, increases dependence on partnerships or financing, and makes financial performance highly sensitive to milestone timing.
Persistent Cash Burn And Funding DependenceOngoing operating and free-cash-flow losses mean the company is consuming cash rather than self-funding development. Even with management’s stated runway into the first half of 2027, continued burn creates recurring financing needs and can constrain strategic flexibility or dilute existing holders.
Clinical And Commercial Execution RiskThe main growth programs remain dependent on future clinical validation, with GLIX1 data not expected until the first half of 2027. APHEXDA expansion also requires substantial transplant-center adoption work, leaving near-term revenue growth and pipeline value exposed to execution uncertainty.
Bioline Rx News
BLRX FAQ
What was BioLineRX Ltd.’s price range in the past 12 months?
BioLineRX Ltd. lowest stock price was 1.10 and its highest was 2.40 in the past 12 months.
What is BioLineRX Ltd.’s market cap?
BioLineRX Ltd.’s market cap is ₪38.83M.
When is BioLineRX Ltd.’s upcoming earnings report date?
BioLineRX Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 52 days.
How were BioLineRX Ltd.’s earnings last quarter?
BioLineRX Ltd. released its earnings results on Aug 31, 2026. The company reported 0 earnings per share for the quarter.
Is BioLineRX Ltd. overvalued?
According to Wall Street analysts BioLineRX Ltd.’s price is currently Overvalued.
Does BioLineRX Ltd. pay dividends?
BioLineRX Ltd. does not currently pay dividends.
What is BioLineRX Ltd.’s EPS estimate?
BioLineRX Ltd.’s EPS estimate is -0.3.
How many shares outstanding does BioLineRX Ltd. have?
BioLineRX Ltd. has 2,986,929,700 shares outstanding.
What happened to BioLineRX Ltd.’s price movement after its last earnings report?
BioLineRX Ltd. reported an EPS of 0 in its last earnings report. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of BioLineRX Ltd.?
Currently, no hedge funds are holding shares in IL:BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLineRX Ltd.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.